Business
AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities
AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base. This milestone expands AsymBio's integrated, end-to-end biologics CDMO services and reinforces its commitment to accelerating the commercialization of innovative therapies worldwide.
About this update from Asymchem Laboratories (tianjin) Co., Ltd. Class A
[{"type":"text","content":"SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base. This milestone expands AsymBio's integrated, end-to-end biologics CDMO services and reinforces its commitment to accelerating the commercialization of innovative therapies worldwide.","length":506,"tagName":"p"},{"type":"image","alt":"Asymbio","displaySize":"","headline":null,"caption":"Asymbio","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/f3cf652d032959e9cf44cd647a618df3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gAe.3hTPxBCWY2npw1AVpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f3cf652d032959e9cf44cd647a618df3","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2840271/Shanghai_Asymchem_Biotechnology_Co_Ltd_lQLPKGwhmQkd9UvNATHNAyCwg1LnWJlmS40JDTZBiI_jAQ_800_305_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Building on the success of its Shanghai Jinshan Base and Zhangjiang Center for Biological Technology and Innovation, the 130,000-square-meter Fengxian facility serves as a strategic hub within AsymBio's global network. It is designed to provide flexible, scalable support across all clinical phases, enabling tailored CDMO solutions from early development through commercial production.","length":390,"tagName":"p"},{"type":"text","content":"Advanced Capabilities for Emerging Therapeutics","length":47,"tagName":"p"},{"type":"text","content":"The Fengxian base is equipped to manufacture a broad portfolio of next-generation biotherapeutics, including ADCs, dual-payload ADCs, RDCs, APCs, PDCs, AOCs, as well as monoclonal, bispecific, and multispecific antibodies and recombinant proteins.","length":247,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase IA: Dedicated to antibody manufacturing, featuring single-use bioreactors (200L, 500L, and 2000L) with a total drug substance capacity of 66,000 liters. A 20 m² lyophilizer supports production of up to one million vials of lyophilized a...
More updates from Asymchem Laboratories (tianjin) Co., Ltd. Class A